PRINCETON, N.J., November 14, 2019 – Bioclinica Medical Imaging, the world leader in centralized imaging services for clinical trials, announced today that it has reached a milestone in the company’s history: the company has contributed reliable data to the primary efficacy endpoint in more than 200 regulatory submissions from biopharmaceutical clients for therapies and indications subsequently approved by the U.S. Food and Drug Administration.
“At Bioclinica, we are proud to have played a part in helping our clients assess the safety and efficacy of new treatments that improve people’s lives,” said David Herron, President & CEO of Bioclinica. “We are grateful to our scientific and project teams, and to all the patients and their families who participated in the clinical studies.”
Bioclinica provides science and technology expertise to assist the life science industry in advancing the development of medical therapies through services in Medical Imaging, Drug Safety Solutions, and Software Solutions. Bioclinica Medical Imaging provides comprehensive support across multiple therapeutic areas, with particular expertise in oncology, musculoskeletal, cardiovascular, gastrointestinal, neuroscience, endocrinology, infectious and respiratory disease.
“Every day, Bioclinica’s team of professionals works to ensure the quality and integrity of the data we process, ensuring that our clients and regulatory authorities have information they can rely upon to evaluate the safety and efficacy of investigational treatments,” said Todd Kisner, Senior Vice President, Quality Assurance & Regulatory Compliance. “We look forward to continuing to partner with the biopharmaceutical industry as the pace of innovation accelerates and the demand for high-quality image and clinical data analysis combined with regulatory expertise increases.”